The expansion will double the existing bulk drug substance
production capacity with the addition of 6 x 20,000L bioreactors, bringing the
total to 12 x 20,000-liter bioreactors. The new construction will also include
a fully automated, cutting-edge fill/finish capability to support large-scale
production of up to approximately 35 million units per annum. To support the
expanded operations, FUJIFILM Diosynth Biotechnologies will add 300 positions
in Denmark by the end of 2023.
The expansion investment also includes a new packaging line
designed to assemble multiple types of auto-injectors and automatic labelling;
these capabilities will be operational in spring 2022. The fill/finish
production line is expected to be operational by summer 2023. As the final step
in the construction, the large scale cell bulk drug substance expansion is
expected to be operational by the end of 2023.
Today’s event included messages from His Excellency Miyagawa
Manabu, Ambassador of Japan in Denmark; Mr. Takatoshi Ishikawa, Senior
Executive Vice President, General Manager of Bio CDMO Division, FUJIFILM
Corporation, Ms. Kirsten Jensen, Mayor of Hillerød and Mr. Toshihisa Iida,
President and Managing Director of Fujifilm in Europe.
“It was a delight to celebrate the commencement of this very
important expansion,” said Takatoshi Ishikawa, Senior Executive Vice President,
General Manager of Bio CDMO Division, FUJIFILM Corporation. “Fujifilm has
highlighted the CDMO business as a priority growth area, and is actively
investing in technology to expand its manufacturing capacity to meet the
growing demands of customers. Additionally, as Fujifilm’s largest investment in
Europe for Bio CDMO business, this new facility represents our commitment to
growing our Bio CDMO offering in the region to better serve our customers.”
“I am very proud that Fujifilm has chosen to make such a
significant investment in Hillerød. We are committed to foster a good business
environment, and have always had a fruitful and good collaboration with
Fujifilm, and I look forward to welcoming even more Fujifilm employees to our
municipality,” said Kirsten Jensen, Mayor of Hillerød.
FUJIFILM Diosynth Biotechnologies an industry-leading
Biologics Contract Development and
Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North
Carolina, College Station, Texas and Hiller Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over
thirty years of experience in the development and manufacturing of recombinant
proteins, vaccines, monoclonal antibodies, among other large molecules, viral
products and medical countermeasures expressed in a wide array of microbial,
mammalian, and host/virus systems. The company offers a comprehensive list of
services from cell line development using its proprietary pAVEway™ microbial
and Apollo™ cell line systems to process development, analytical development,
clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth
Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi
Corporation. For more information, go
to: www.fujifilmdiosynth.com
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting
edge solutions to a broad range of global industries by leveraging its depth of
knowledge and fundamental technologies developed in its relentless pursuit of
innovation. Its proprietary core technologies contribute to the various fields
including healthcare, graphic systems, highly functional materials, optical
devices, digital imaging and document products. These products and services are
based on its extensive portfolio of chemical, mechanical, optical, electronic
and imaging technologies. For the year ended March 31, 2020, the company had
global revenues of $21 billion, at an exchange rate of 109 yen to the dollar.
Fujifilm is committed to responsible environmental stewardship and good corporate
citizenship. For more information, please visit: www.fujifilmholdings.com
0 comments:
Post a Comment